31046175|t|Anticholinergic medicines use among older adults before and after initiating dementia medicines.
31046175|a|AIMS: We investigated anticholinergic medicines use among older adults initiating dementia medicines. METHODS: We used Pharmaceutical Benefits Scheme dispensing claims to identify patients who initiated donepezil, rivastigmine, galantamine or memantine between 1 January 2013 and 30 June 2017 (after a period of >=180 days with no dispensing of these medicines) and remained on therapy for >=180 days (n = 4393), and dispensed anticholinergic medicines in the 180 days before and after initiating dementia medicines. We further examined anticholinergic medicines prescribed by a prescriber other than the one initiating dementia medicines. RESULTS: One-third of the study cohort (1439/4393) was exposed to anticholinergic medicines up to 180 days before or after initiating dementia medicines. Among patients exposed to anticholinergic medicines, 46% (659/1439) had the same medicine dispensed before and after initiating dementia medicines. The proportion of patients dispensed anticholinergic medicines increased by 2.5% (95% confidence interval [CI]: 1.3-3.7) after initiating dementia medicines. Antipsychotics use increased by 10.1% (95% CI: 7.6-12.7) after initiating dementia medicines; driven by increased risperidone use (7.3%, 95% CI: 5.3-9.3). Nearly half of patients dispensed anticholinergic medicines in the 180 days after (537/1133), were prescribed anticholinergic medicines by a prescriber other than the one initiating dementia medicines. CONCLUSION: Use of anticholinergic medicines is common among patients initiating dementia medicines and this occurs against a backdrop of widespread campaigns to reduce irrational medicine combinations in this vulnerable population. Decisions about deprescribing medicines with questionable benefit among patients with dementia may be complicated by conflicting recommendations in prescribing guidelines.
31046175	0	25	Anticholinergic medicines	Chemical	-
31046175	77	85	dementia	Disease	MESH:D003704
31046175	119	144	anticholinergic medicines	Chemical	-
31046175	179	187	dementia	Disease	MESH:D003704
31046175	277	285	patients	Species	9606
31046175	300	309	donepezil	Chemical	MESH:D000077265
31046175	311	323	rivastigmine	Chemical	MESH:D000068836
31046175	325	336	galantamine	Chemical	MESH:D005702
31046175	340	349	memantine	Chemical	MESH:D008559
31046175	524	549	anticholinergic medicines	Chemical	-
31046175	594	602	dementia	Disease	MESH:D003704
31046175	634	659	anticholinergic medicines	Chemical	-
31046175	717	725	dementia	Disease	MESH:D003704
31046175	803	828	anticholinergic medicines	Chemical	-
31046175	871	879	dementia	Disease	MESH:D003704
31046175	897	905	patients	Species	9606
31046175	917	942	anticholinergic medicines	Chemical	-
31046175	1019	1027	dementia	Disease	MESH:D003704
31046175	1057	1065	patients	Species	9606
31046175	1076	1101	anticholinergic medicines	Chemical	-
31046175	1177	1185	dementia	Disease	MESH:D003704
31046175	1271	1279	dementia	Disease	MESH:D003704
31046175	1311	1322	risperidone	Chemical	MESH:D018967
31046175	1367	1375	patients	Species	9606
31046175	1386	1411	anticholinergic medicines	Chemical	-
31046175	1462	1487	anticholinergic medicines	Chemical	-
31046175	1534	1542	dementia	Disease	MESH:D003704
31046175	1573	1598	anticholinergic medicines	Chemical	-
31046175	1615	1623	patients	Species	9606
31046175	1635	1643	dementia	Disease	MESH:D003704
31046175	1859	1867	patients	Species	9606
31046175	1873	1881	dementia	Disease	MESH:D003704

